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AbstrAct
Objective The Swiss National Science Foundation (SNSF) 
promotes academic excellence through competitive 
selection of study proposals and rigorous evaluation of 
feasibility, but completion status and publication history of 
SNSF-supported randomised clinical trials (RCTs) remain 
unclear. The main objectives were to review all healthcare 
RCTs supported by the SNSF for trial discontinuation and 
non-publication, to investigate potential risk factors for 
trial discontinuation due to poor recruitment and non-
publication, and to compare findings to other Swiss RCTs 
not supported by the SNSF.
Design We established a retrospective cohort of all SNSF-
supported RCTs for which recruitment and funding had 
ended in 2015 or earlier. For each RCT, two investigators 
independently searched corresponding publications in 
electronic databases. In addition, we approached all 
principal investigators to ask for additional publications 
and information about trial discontinuation. Teams of 
two investigators independently extracted details about 
study design, recruitment of participants, outcomes, 
analysis and sample size from the original proposal and, 
if available, from trial registries and publications. We used 
multivariable regression analysis to explore potential 
risk factors associated with discontinuation due to poor 
recruitment and with non-publication, and to compare our 
results with data from a previous cohort of Swiss RCTs not 
supported by the SNSF.
results We included 101 RCTs supported by the SNSF 
between 1986 and 2015. Eighty-seven (86%) principal 
investigators responded to our survey. Overall, 69 (68%) 
RCTs were completed, 26 (26%) RCTs were prematurely 
discontinued (all due to slow recruitment) and the 
completion status remained unclear for 6 (6%) RCTs. 
For analysing publication status, we excluded 4 RCTs 
for which follow-up was still ongoing and 9 for which 
manuscripts were still in preparation. Of the remaining 
88 RCTs, 53 (60%) were published as full articles in 
peer-reviewed journals. Multivariable regression models 
suggested that discontinued trials were at higher risk 
for non-publication than completed trials (adjusted OR 
7.61; 95% CI 2.44 to 27.09). Compared with other Swiss 
RCTs, the risk of discontinuation for SNSF-supported 
RCTs was higher than in industry-initiated RCTs (adjusted 
OR 3.84; 95% CI 1.68 to 8.74), but not significantly 
different from investigator-initiated RCTs not supported 
by the SNSF (adjusted OR 1.05; 95% CI 0.51 to 2.11). We 
found no evidence that the proportion of discontinued or 
unpublished RCTs decreased over the last 20 years.
conclusions One out of four SNSF-supported RCTs were 
prematurely discontinued due to slow recruitment, 40% of 
all included RCTs and 70% of all discontinued RCTs were 
not published in peer-reviewed journals. There is a case to 
reconsider how public funding bodies such as the SNSF could 
improve their feasibility assessment and promote publication 
of RCTs irrespective of completion status.
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Research
strengths and limitations of this study
 ► Access to all healthcare randomised clinical 
trial  (RCT) proposals supported by the Swiss 
National Science Foundation (SNSF) since its 
existence without any restrictions by the funder or 
the applicants themselves.
 ► The search for subsequent publications and the 
data extraction were performed by methodologically 
trained reviewers independently and in duplicate.
 ► We combined information derived from funding 
proposals, trial registries, publications and an 
investigator survey (response rate of 86%).
 ► Robustness due to various sensitivity analyses 
using different outcome definitions and multiple 
imputation for missing data.
 ► Low reporting quality of some of the older RCT 
proposals leading to missing data.
 ► Low power for our prespecified risk-factor analyses 
due to the rather small number of SNSF-supported 
healthcare RCTs over a time period of almost three 
decades.
 ► Focus on SNSF-supported RCTs means that the 
results are not necessarily generalisable to publicly 
funded RCTs outside of Switzerland.
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IntrODuctIOn
Randomised clinical trials (RCTs) are the gold standard to 
assess preventive, therapeutic, diagnostic or rehabilitative 
interventions and constitute a cornerstone of evidence-
based medicine.1 The conduct of an RCT usually requires 
substantial resources and investigators often face multiple 
practical challenges. A study of trial protocols approved 
by research ethics committees between 2000 and 2003 
suggested that 25% of initiated RCTs were prematurely 
discontinued and up to 60% remained unpublished. 
The most frequent reason for discontinuation was poor 
recruitment of trial participants,2 which has ethical and 
economic implications: patients consent to participate in 
a trial on the premise that the findings will foster new 
medical knowledge. However, if recruitment fails, results 
are inconclusive, and collected data are not published, 
which undermines patients’ trust in clinical research. 
Moreover, non-publication of (discontinued) RCTs 
compromises systematic reviews and meta-analyses that 
help answer clinically important research questions. 
Finally, discontinuation and non-publication represent a 
waste of precious (public) funding resources.3 4
The Swiss National Science Foundation (SNSF) is the 
main public funding body for basic and applied research 
on healthcare in Switzerland. The SNSF promotes 
academic excellence and has high expectations in bene-
ficiaries about ethical standards and research integrity. 
During peer-review of proposals, SNSF committees crit-
ically evaluate the feasibility of proposed trials among 
other criteria. In addition, the SNSF explicitly states that 
grantees are obliged to make research results available to 
the public.5
The risk of trial discontinuation and non-publication in 
SNSF-supported RCTs is unknown. Our earlier research 
included nine SNSF-supported RCTs.2 All were success-
fully completed suggesting that SNSF-supported RCTs 
are at lower risk for discontinuation than other RCTs.2 
However, a study analysing 122 RCTs funded by two major 
public research funding bodies in the UK found that 
u45% of RCTs were discontinued due to poor recruit-
ment.6
We aimed to investigate the completion and publica-
tion status of all RCTs supported by the SNSF. We tested a 
small number of prespecified risk factors for trial discon-
tinuation and non-publication. In addition, we conducted 
an exploratory analysis comparing the SNSF-supported 
RCTs with other RCTs that were conducted in Switzerland 
but not supported by the SNSF.
MethODs
Study design and data source
We conducted a retrospective cohort study of RCTs. We 
systematically searched titles and abstracts provided on 
the project database of the SNSF (p3 research database, 
p3. snf. ch), which contains all research projects that the 
SNSF approved and supported fully or partially since 
its existence. We excluded RCTs supported through 
personal grants that were carried out exclusively outside 
of Switzerland (ie, SNSF mobility grants), RCTs that were 
never started and RCTs for which recruitment or funding 
was still ongoing at the time of the cut-off date (30 April 
2015). The search strategy included synonyms for ‘rando-
misation’ and ‘trial’ and was limited to human healthcare 
categories using the database’s ‘advanced search’ option 
(for details see online supplementary appendix 1).
For each eligible RCT, two methodologically trained 
investigators independently searched for corresponding 
publications through information available in the p3 
research database and electronic literature searches 
in Medline, Embase, Cochrane Central Register of 
Controlled Trials, Google Scholar and trial registries, 
using relevant keywords for study design, population, 
interventions and outcome if applicable. Furthermore, 
we screened personal websites of principal investigators 
and coinvestigators, and reference lists of related articles.
In addition, we approached all principal investigators 
of included RCTs using an online questionnaire sent 
by email. We asked them to provide a) a copy of the 
latest RCT protocol, b) all publication(s), c) recruit-
ment details such as timeframe, duration and achieved 
sample size, d) recruitment problems with reasons and 
any measures taken in response, e) whether a trial was 
prematurely discontinued with reasons and f) additional 
funding sources and estimate overall cost of their trial. If 
a principal investigator did not respond, we sent several 
reminders by email, or a paper version of the question-
naire by regular mail, and eventually tried to call the 
investigator by phone or approach a coinvestigator.
Data extraction
Data extractors trained in trial methodology signed 
confidentiality agreements and extracted data from trial 
proposals and corresponding publications independently 
and in duplicate. Disagreements were resolved by discus-
sion and consensus. Extracted items included RCT 
properties (eg, setting and clinical area, study design, 
primary outcome, type of intervention and control 
group, single-centre/multicentre status, planned sample 
size, planned respectively performed interim analysis), 
funding sources, statistical methods (eg, sample size 
calculation, intention-to-treat principle, subgroup anal-
ysis) and recruitment strategies (recruitment projections, 
availability of logistic/methodological support, strategies 
to support/monitor recruitment) and premature discon-
tinuation and reported reasons (in publications only). 
We used a password-protected web-based data extraction 
tool (www. squiekero. org) that included a detailed manual 
with instructions for each variable of interest.
Outcome definitions
We considered an RCT discontinued if this was explicitly 
reported by the investigators in a journal publication or 
in their response to our survey. If we could not elucidate 
the reason for trial discontinuation, we considered an 
RCT discontinued for poor recruitment if poor recruit-
ment was mentioned (in the publication or survey) and 
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Figure 1 Flow chart of trial selection. RCT, randomised 
clinical trial; SNSF, Swiss National Science Foundation.
the actual sample size was less than the prespecified 90% 
of the target sample size (sensitivity analysis with cut-off 
at 80%).
For analysing publication status, we excluded RCTs for 
which follow-up was still ongoing, or manuscripts were 
still in preparation (according to survey responses). We 
considered peer-reviewed journal publications other than 
conference abstracts, research letters or book chapters as 
full publications in our primary analysis.
statistical analysis
We described categorical variables as absolute and rela-
tive frequencies and continuous variables as medians and 
IQRs. We prespecified two multivariable logistic regres-
sion models to test the following prespecified risk factors:
1. For RCT discontinuation (discontinued vs 
completed, unclear excluded): centre status (single 
vs multicentre; hypothesis: multicentre RCTs 
are less frequently discontinued), target sample 
size (continuous; hypothesis: larger trials are less 
frequently discontinued2) and start year of the RCT 
(continuous; hypothesis: older RCTs are more likely 
to be discontinued). We used complete cases in the 
full dataset.
2. For non-publication (non-publication vs peer-
reviewed journal publication): RCT completion status 
(discontinued vs completed; hypothesis: discontinued 
RCTs are less likely to be published), target sample size 
(continuous; hypothesis: smaller RCTs are less likely to 
be published) and start year of the RCT (continuous; 
hypothesis: older RCTs are less likely to be published). 
Here we used a reduced dataset excluding four RCTs 
for which follow-up was still ongoing and nine RCTs 
for which manuscripts were still in preparation.
We calculated unadjusted and adjusted ORs with 95% 
CIs. In two separate sensitivity analysis, we (a) used multi-
ple-imputation techniques to impute missing data and 
(b) an alternate threshold of <80% of the target sample 
size to define RCT discontinuation (see the ‘Outcome 
definitions’ section). In the logistic regression model 
for non-publication, we performed two additional sensi-
tivity analyses: first, we used an alternative definition 
of ‘published’ adding RCTs with results published in 
conference abstracts, book chapters or letters to the 
editor. Second, we excluded RCTs approved by the SNSF 
between 1986 and 1996, that is, the four oldest SNSF-sup-
ported RCTs, that all remained unpublished.
In further exploratory analyses, we compared RCT 
discontinuation and non-publication between SNSF-sup-
ported RCTs and two previously established samples of (a) 
investigator-initiated RCTs without SNSF support and (b) 
industry-initiated RCTs conducted in Switzerland (online 
supplementary figure 1). Both these samples were subsets 
of a large cohort of RCTs approved by research ethics 
committees between 2000 and 2003.2 To enhance compa-
rability, we prespecifed a similar timeframe and only 
included SNSF-supported RCTs with start dates between 
1995 and 2008. We fitted multivariable logistic regression 
models using SNSF support as the independent variable 
of interest. With RCT discontinuation as dependent vari-
able, we adjusted models for centre status and sample 
size, and with non-publication as dependent variable we 
adjusted for discontinuation, centre status and sample 
size.
A two-sided p value of <0.05 was set as level of statistical 
significance. All analyses were carried out using R V.3.0.3 
(www. r- project. org).
FInDIngs
Trial flow and characteristics of included trials
The search of SNSF’s p3 database yielded 455 entries, 
of which 354 were excluded after screening titles and 
abstracts (figure 1, last update in November 2015 for the 
cut-off date of 30 April 2015). We identified a total of 101 
eligible healthcare RCTs funded by the SNSF between 
1986 and 2015 (since the existence of the p3 database). 
The response rate in our survey of principal investigators 
was 86%; 87 of 101 responded to the two main questions: 
‘Was the RCT stopped prematurely?’ and ‘Were the results 
of the RCT published?'. For the assessment of publication 
status, we excluded 13 RCTs for which follow-up was still 
ongoing or the manuscript still in preparation, leaving a 
total of 88 RCTs. Table 1 summarises the characteristics 
of the included RCTs. The majority were single-centre, 
parallel-group trials testing a medication or behavioural 
intervention in adults. The median target sample size was 
120 and the median planned duration of recruitment 
was 14 months. Of the 68 trials approved after the ICMJE 
recommendation to prospectively register all RCTs (ie, 
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Table 1 Characteristics of included RCTs supported by the 
SNSF
Characteristic All (n=101)
Age group
  Adults (%) 88 (87.1)
  Children <18 years (%) 8 (7.9)
  Elderly >60 years (%) 5 (5.0)
Study population
  Patients suffering from disease or at risk 
for disease (%) 97 (96.0)
  Healthy volunteers (%) 4 (4)
Type of intervention
  Behavioural intervention (%) 36 (35.6)
  Medication (%) 33 (32.7)
  Rehabilitation (%) 11 (10.9)
  Other (%)* 12 (11.9)
  Surgical (%) 7 (6.9)
  Diagnostic test (%) 2 (2.0)
Planned centres
  Single-centre (%) 54 (53.5)
  Multicentre national (%) 34 (33.7)
  Multicentre international (%) 13 (12.9)
Sample size
  Planned sample size, median (IQR)† 120 (60–275)
Trial design
  Parallel (%) 85 (84.2)
  Cross-over (%) 10 (9.9)
  Factorial (%) 5 (5.0)
  Unclear (%) 1 (1.0)
Pilot study planned (%) 10 (9.9)
Pilot study conducted (%) 1 (1.0)
Planned duration of recruitment, median in 
months (IQR)‡ 14 (12–21)
Trial registration
  In trials started before 2005; n=33 (%) 11 (33.3)
  In trials started in or after 2005; n=68 (%) 51 (76.5)
*Includes RCTs testing a treatment algorithm or light therapy, etc.
†One missing data for planned sample size.
‡Twenty-one missing data for planned duration of recruitment.
RCT, randomised clinical trial; SNSF, Swiss National Science 
Foundation.
Table 2 Completion status of SNSF-supported RCTs
Completion/recruitment status
Total 
(N=101)
Completed 69 (68%)*
  At least 90%* of target sample size achieved 
and no recruitment problems reported 37
  At least 90%* of target sample size achieved 
but recruitment problems reported 24
  Same research question, but reduced target 
sample size reduced that eventually was 
achieved 3
  New research question with smaller target 
sample size that eventually was achieved 2
  RCT achieved conclusive result with less 
participants than target sample size 3
Discontinued 26 (26%)*
  Self-reported discontinuation due to 
recruitment problems (registry, publication, 
survey) 11
  Recruitment problems reported in survey and 
RCT did not achieve 90%* of target sample 
size 15
Unclear 6 (6%)
*When we used 80% instead of 90% of target sample size 
achieved as a threshold for assuming RCT discontinuation, 24% 
(24/101) instead of 26% (26/101) of RCTs were discontinued and 
70% (71/101) instead of 68% (69/101) of RCTs were completed 
(see online supplementary table 1).
RCT, randomised clinical trial; SNSF, Swiss National Science 
Foundation.
in 2005 or later),3 51 (76.5%) were registered in a trial 
registry.
Discontinuation of snsF-supported trials
Overall, 68% (69/101) RCTs were completed as planned, 
26% (26/101) were prematurely discontinued and the 
completion status remained unclear in 6% (6/101) 
(table 2). A reason for discontinuation was explicitly 
reported for 42% (11/26) of the discontinued RCTs 
(one was reported in a registry, one in a publication and 
nine by the investigators in the survey). In all 11 cases, 
the RCT was discontinued due to recruitment prob-
lems. For the remaining 58% (15/26), we were unable 
to obtain any clarification of the completion status from 
the investigators. All mentioned slow recruitment when 
responding in the survey, and the trials achieved <90% 
of the initial target sample size. Therefore, we consid-
ered all 26 RCTs prematurely discontinued due to slow 
recruitment. Of the completed RCTs, 61 of 69 completed 
RCTs were carried out as planned. Five of the remaining 
eight completed RCTs were modified at an early stage in 
terms of the research question or planned sample size; 
all achieved the new target sample size. The remaining 
three completed RCTs achieved a conclusive result with a 
smaller sample size than anticipated.
In the sensitivity analysis, when we used a threshold 
of 80% instead of 90% of target sample size achieved to 
define RCT discontinuation (see the ‘Outcome defini-
tions’ section), 24% (24/101) of RCTs were discontinued 
(online supplementary table 1).
Fifty-seven per cent (50/87) of the principal investiga-
tors indicated in the survey that recruitment was slower 
than expected, irrespective of the completion status of 
their RCT.
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Table 3 Factors associated with discontinuation of SNSF-supported RCTs
Characteristic
Univariable Multivariable*
OR (95% CI) p Value OR (95% CI) p Value
Single-centre (vs multicentre) 0.92 (0.37 to 2.27) 0.850 0.75 (0.29 to 1.94) 0.559
Planned sample size (per 100 more)† 0.97 (0.84 to 1.04) 0.539 0.96 (0.83 to 1.04) 0.491
Start of RCT (per year) 0.92 (0.82 to 1.03) 0.135 0.92 (0.82 to 1.02) 0.166
*Complete-case multivariable logistic regression analysis (n=100) excluding one RCT with missing value for planned sample size.
†One missing data for planned sample size.
RCT, randomised clinical trial; SNSF, Swiss National Science Foundation.
Table 4 Publication status of SNSF-supported RCTs stratified by completion status
Publication status*
Completion/recruitment status
Completed (%) Discontinued (%) Unclear (%) Total (n=88)* (%)
Full journal article 47 (76) 6 (30) 0 (0) 53 (60)
Not published as full journal article 15 (24) 14 (70) 6 (100) 35 (40)
  Not published at all 4 9 6 19
  Only conference abstract 10 2 0 12
  Only brief report or letter to editor 1 2 0 3
  Only book chapter 0 1 0 1
*Randomised clinical trials for which the manuscript was still in preparation or follow-up was still ongoing were excluded from this analysis 
(n=88).
RCT, randomised clinical trial; SNSF, Swiss National Science Foundation.
risk factors for discontinuation
In the univariable and multivariable analysis of risk 
factors for discontinuation, none of the prespecified 
variables (sample size, centre status and year of RCT) 
were significantly associated with trial discontinuation 
(table 3). Sensitivity analyses with multiple imputa-
tion for missing data or with the alternate threshold of 
80% of achieved target sample size did not change our 
results (see online supplementary tables 2 and 3.
Publication of snsF-supported trials
Of 88 RCTs, 60% (53/88) were published as peer-re-
viewed journal articles 1– 13 years after their start, 22% 
(19/88) were not published at all and the remaining 
18% (16/88) RCTs only as conference abstracts, book 
chapters or brief reports/letters to the editor (table 4). 
From the discontinued RCTs, 30% (6/20) were 
published as peer-reviewed journal articles. We identi-
fied 52 of the 53 full journal articles through searching 
electronic databases and one, a publication in an Indian 
journal not indexed in common databases, through our 
survey.
risk factors for non-publication
In multivariable analysis, trial discontinuation was 
significantly associated with non-publication (adjusted 
OR 7.61; 95% CI 2.44 to 27.09), but target sample 
size and start year were not (table 5). A univariable 
association between start year and non-publication 
(unadjusted OR 0.90; 95% CI, 0.81 to 0.98) did not 
persist when adjusting for discontinuation and target 
sample size. In addition, when we excluded the four 
oldest RCTs approved between 1986 and 1996 (all 
unpublished), this association in univariable anal-
ysis was no longer statistically significant (see online 
supplementary table 4). Sensitivity analyses with 
multiple imputation for missing data, with the alter-
nate threshold of 80% of achieved target sample size, 
or by considering conference abstracts, letters to the 
editor and book chapters as ‘full publications’ did not 
change our findings (see online supplementary tables 
5, 6 and 7).
comparison with rcts conducted in switzerland but without 
snsF support
Online supplementary figure 1 and table 8 provide 
details about the comparison of investigator-initiated 
SNSF-supported RCTs with (a) investigator-initiated 
RCTs without SNSF support and (b) industry-initiated 
RCTs conducted in Switzerland. Multivariable analyses 
(table 6) suggested that the odds of premature trial 
discontinuation did not differ between SNSF-supported 
RCTs and investigator-initiated RCTs conducted in 
Switzerland but not supported by the SNSF (adjusted 
OR 1.05; 95% CI 0.51 to 2.11); however, the odds of 
premature discontinuation were significantly higher 
than in industry-initiated RCTs conducted in Switzer-
land (adjusted OR 3.84; 95% CI 1.68 to 8.74). The odds 
of non-publication did not differ significantly in both 
comparisons. Sensitivity analyses with multiple impu-
tation for missing data did not change these findings 
(see online supplementary table 9).
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Table 5 Factors associated with non-publication of SNSF-supported RCTs
Characteristic
Univariable Multivariable*
OR (95% CI) p Value OR (95% CI) p Value
Discontinued RCTs (vs completed RCTs)† 7.31 (2.49 to 23.94) <0.001 7.61 (2.44 to 27.09) <0.001
Planned sample size (per 100 more)‡ 0.98 (0.90 to 1.04) 0.548 0.91 (0.75 to 1.02) 0.291
Start of RCT (per year) 0.90 (0.81 to 0.98) 0.0238 1.00 (0.88 to 1.14) 0.959
*Complete-case multivariable logistic regression analysis (n=81); from the total of 101 RCTs, we excluded 9 RCTs for which manuscripts were 
still in preparation and 4 RCTs for which follow-up were still ongoing. Moreover, there was one RCT with missing value for planned sample 
size and six RCTs with unclear completion status. For the 20 missing values, we performed multiple imputation (see online supplementary 
table 5).
†Six trials with unclear completion status.
‡One missing data for planned sample size.
RCT, randomised clinical trial; SNSF, Swiss National Science Foundation.
DIscussIOn
Summary of findings
Recruitment problems caused premature discontinu-
ation in one out of four RCTs supported by the SNSF. 
Forty per cent of RCTs (70% of discontinued RCTs) 
were not published in a peer-reviewed journal. We found 
no evidence that the proportion of discontinued or 
unpublished RCTs decreased over the last 20 years. Trial 
discontinuation was an important risk factor for non-pub-
lication. SNSF-supported RCTs were more likely to be 
discontinued due to poor recruitment than industry-ini-
tiated RCTs and about equally likely to be discontinued 
or not published than investigator-initiated RCTs without 
SNSF support.
strengths and limitations
We had access to all healthcare RCT proposals supported 
by the SNSF without any restrictions by the funder or 
the applicants themselves.7 The search for subsequent 
publications and the data extraction were performed 
by methodologically trained reviewers independently 
and in duplicate. We combined information derived 
from funding proposals, trial registries, publications 
and an investigator survey. In the latter, we achieved a 
response rate of 86%, which was higher than in other 
similar studies surveying biomedical researchers.8 9 Our 
results proved robust in various sensitivity analyses using 
different outcome definitions and multiple imputation 
for missing data.
Limitations of our study include the low reporting 
quality of some of the older RCT proposals leading to 
missing data. Furthermore, we had low power for our 
prespecified risk-factor analyses due to the rather small 
number of SNSF-supported healthcare RCTs over a time 
period of almost three decades. Our focus on SNSF-sup-
ported RCTs means that the results are not necessarily 
generalisable to publicly funded RCTs outside of Switzer-
land. However, evaluation criteria and processes of the 
SNSF are similar to other national funding agencies in 
Europe or North-America based on information from 
agencies’ websites. Finally, we could not include some 
well-established factors associated with non-publication 
of RCTs in our regression analysis such as negative results 
because we did not ask investigators of unpublished RCTs 
for direction of results of their trials.8 10
comparison with other studies
In a study in the UK, McDonald et al followed 122 multi-
centre investigator-initiated RCTs funded by two major 
public funding bodies between 1994 and 2002 and showed 
that 20%–45% of the trials were discontinued due to 
insufficient recruitment (defined as 80% or less of orig-
inal target).6 The proportion of MRC/HTA-supported 
RCTs failing to recruit 80% of their target decreased in 
the period between 2002 to 2008, but still accounted for 
22% of included RCTs. As in our study the proportion 
of completed RCTs did not significantly improve over 
time.11 Walters et al. reviewed 151 HTA-supported RCTs 
published between 2004 – 2014 and found that 21% of 
the included RCTs recruited less than 80% of their final 
target sample size.12 Another retrospective cohort study 
from Switzerland reported a lower rate of trial discon-
tinuation (57/508, 11%).13 Likely explanations for this 
difference are a larger proportion of industry-initiated 
RCTs and a restriction to drug intervention trials, both 
of which are factors potentially protecting against discon-
tinuation.2 Our study suggests that recruitment problems 
seem to be equally common in RCTs with and without 
competitive public funding, and confirms that recruit-
ment problems are the most important reason for trial 
discontinuation.2 6 14
Overall, 60% of SNSF-supported RCTs were published 
as peer-reviewed journal articles, which is in line with 
publication rates found in other empirical studies on 
RCTs.13 15 The publication rate of 30% among discon-
tinued SNSF-supported RCTs is similar to a comparable 
Dutch study14 with 32% of discontinued RCTs being 
published. Similar to the results of Kasenda et al,2 our 
analysis suggests that RCT discontinuation (due to slow 
recruitment) is a major determinant of non-publica-
tion.
Implications
Premature discontinuation of RCTs due to poor recruit-
ment constitutes a considerable waste of scarce public 
resources for clinical research, in particular when data 
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and lessons learnt remain unpublished. If the challenges 
resulting in RCT discontinuation are not shared with the 
scientific community, mistakes may be repeated. Results 
from discontinued and therefore underpowered RCTs 
might be inconclusive. However, their results are still 
valid, can provide important pilot data for future trials 
and may contribute to systematic reviews and meta-anal-
yses. Trial discontinuation and failure to publish the 
results puts the public’s and patients’ trust in clinical 
research at stake and compromises the willingness of 
future patients to participate in clinical studies.
In line with earlier findings,6 our results question 
whether the assessment of an RCT’s feasibility by public 
funding agencies meets its goals. No doubt, such an 
evaluation is challenging since grant applicants are 
inherently optimistic about the feasibility of their trial 
and projected numbers of eligible and recruited partici-
pants. How could the feasibility assessment of proposed 
RCTs be improved? First, public funding agencies, and 
institutional review boards and ethics committees, should 
require investigators to marshal empirical evidence to 
support the feasibility of achieving sample size targets 
within acceptable recruitment periods: published or at 
least registered pilot trials that also include obtaining 
informed consent by participants probably provide the 
best proof of feasibility of a trial protocol and yield the 
most realistic estimates for participant recruitment.16 
In the present study, only 1 RCT proposal was based 
on a pilot trial and only 10 described plans for a pilot. 
To promote the conduct of pilot trials, public funders 
should include a specific funding scheme for feasibility 
trials in their portfolio. In our own experience, reviewer 
comment received after submission of grant proposals 
often include the well-meaning suggestion to pilot 
trial methods while funding for such feasibility studies 
is difficult to obtain. Second, trial protocols should 
describe the planned recruitment process in sufficient 
detail to enable referees to judge about feasibility based 
on clear and comprehensive information. Endorsement 
of the Standard Protocol Items: Recommendations for 
Interventional Trials guidance and respective templates 
may help to facilitate well-structured and informative 
trial protocols as a prerequisite for improved feasibility 
assessment.17 18 Third, funding agencies could stipulate 
stringent recruitment monitoring, regular feedback 
about recruitment progress with updated recruitment 
projections particularly in the first months of the trial 
and plans for specific actions to be taken if projection 
goals are not achieved. ‘Pull funding’ schemes could 
be introduced that condition the payment of grant 
instalments on the achievement of certain recruitment 
milestones. Providing ‘backup grants’ is another option, 
if a well-defined limited extension of the recruitment 
period is needed to allow investigators to complete the 
RCT. Fourth, current recommendations encourage the 
adoption of multiple recruitment strategies to enhance 
participant enrolment in RCTs,4 19 20 but evidence on 
what actually works to improve recruitment is sparse 
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and high-quality studies on promising interventions are 
urgently needed.21–23 An appropriate and efficient way 
to test such interventions may be to incorporate them 
with a randomised design in a host trial as recently 
promoted by the Systematic Techniques for Assisting 
Recruitment to Trials programme.24 So-called ‘Studies 
Within A Trial’ could be encouraged by funding agen-
cies and would add extra value to grant proposals for 
RCTs.
Public funding agencies have a genuine interest to 
ensure that results, data and lessons learnt from funded 
RCTs are made available to the scientific community 
and that ultimately the public benefits from it. This 
can be achieved through peer-reviewed publications 
or accessible data depositories or trial registries and 
supporting initiatives such as AllTrials (www. alltrials. 
net). Academic institutions (eg, universities) hosting 
clinical trials should mandate that investigators will 
publish all results in full, for example, within 2 years 
of the last data collection of the primary end point.25 
Public funding agencies should help endorse such poli-
cies by conditioning transfer of funds to investigators on 
adherence to standards of publication and data sharing.
cOnclusIOn
Trial discontinuation due to poor recruitment and 
non-publication are common among SNSF-supported 
RCTs. More rigorous measures are necessary to ensure 
that successful grant applications have the best possible 
prospects for trial completion and that results and 
encountered challenges are reliably disseminated to 
the scientific community and larger public.
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